瑞巴派特在慢性萎缩性胃炎中的应用价值

Application Value of Rebamipide in Chronic Atrophic Gastritis

目的:探讨瑞巴派特在慢性萎缩性胃炎中的应用价值。方法:选取2019年11月—2021年3月本院收治的慢性萎缩性胃炎患者80例。按照随机数字表法分为对照组和观察组各40例。对照组使用雷贝拉唑钠肠溶片,观察组在对照组基础上联合使用瑞巴派特,比较两组胃蛋白酶指标、血管内皮生长因子(VEGF)及不良反应发生情况。结果:治疗1个疗程后,观察组胃蛋白酶Ⅰ水平和胃蛋白酶Ⅱ水平高于对照组(P<0.05);两组治疗1、4、8周后VEGF水平高于治疗前,且观察组高于对照组(P<0.05);观察组不良反应总发生率低于对照组(P<0.05)。结论:雷贝拉唑联合瑞巴派特治疗慢性萎缩性胃炎的效果良好,可有效促进胃蛋白酶和VEGF分泌,且用药不良反应少,安全性高。

Objective: To investigate the application value of rebamipide in chronic atrophic gastritis. Methods: A total of 80patients with chronic atrophic gastritis admitted to our hospital from November 2019 to March 2021 were selected. According to the method of random number table, they were divided into the control group and the observation group, with 40 cases in each group. The control group used rabeprazole sodium enteric coated tablets, and the observation group used rebamipide on the basis of the control group. The pepsin index, vascular endothelial growth factor(VEGF) and adverse reactions of the two groups were compared. Results: After one course of treatment, the levels of pepsin I and pepsin II in the observation group were higher than those in the control group(P<0.05). The level of VEGF in the two groups was higher than that before treatment after 1, 4 and 8 weeks of treatment, and that in the observation group was higher than that in the control group(P<0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05). Conclusion: Rabeprazole combined with rebamipide is effective in the treatment of chronic atrophic gastritis, which can effectively promote the secretion of pepsin and VEGF, with less adverse reactions and high safety.